Richard H. Ebright
@R_H_Ebright
Board of Governors Professor of Chemistry and Chemical Biology Founder and CEO, APY Therapeutics, LLC @RutgersU @APYTherapeutics @BiosafetyNow
Postdoctoral Associate and Research Associate positions available in structural biology of transcription, transcription-translation coupling, and transcriptional regulation. Cryo-EM and/or crystallography. CV and cover letter to [email protected].



Weird how centrist people are coming out of the woodwork, so to speak, to defend pro-merit, pro-free speech/academic freedom positions! It's almost like such views were being suppressed by some force over the past few years.....
Based on what I have read and heard so far, the agreement reached between the Federal government and @Columbia is an excellent template for agreements with other institutions including @Harvard. First, academic freedom is preserved as the University maintains academic autonomy.…
Based on what I have read and heard so far, the agreement reached between the Federal government and @Columbia is an excellent template for agreements with other institutions including @Harvard. First, academic freedom is preserved as the University maintains academic autonomy.…
"Lawrence Summers, Harvard’s former president,...said...'this may be the best day higher education has had in the last year.' He called the agreement an 'excellent template' for...other institutions, saying it balances university autonomy with...reforms."
"The deal...the Trump administration struck with Columbia University...is now a blueprint for negotiations with other universities...Columbia agreed to pay $200 M...to settle allegations it violated antidiscrimination law and to restore...federal grants. wsj.com/us-news/educat…
DID YOU KNOW? The bacterium at the center of this retracted 2010 paper was named GFAJ-1--short for “Give Felisa a Job”--a nod to lead author Felisa Wolfe-Simon. The strain’s name underscores the perverse incentives in science to over-hype non-results to advance your career.
Science is retracting the December 2010 Research Article, “A bacterium that can grow by using arsenic instead of phosphorus.” (THREAD 🧵) scim.ag/44TL1hq
"If selling antibiotics loses money, no one will invest.” CEO Henry Skinner recently discussed with @swissinfo_en why private investors have turned away from antibiotics and how pull incentives could help bring them back. swissinfo.ch/eng/new-treatm…